What is Organicell Regenerative Medicine, Inc. (OCEL)?

Organicell Regenerative Medicine, Inc. (OCEL) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of OCEL?

The current price of OCEL is $2.74. Prices are updated in real time on Stocks360.

What is OCEL's price-to-earnings (PE) ratio?

OCEL's trailing twelve-month PE ratio is -4.73, based on current price and earnings per share data available on Stocks360.

What is OCEL's market capitalization?

OCEL's market capitalization is $19,974,944.00, placing it in the small-cap tier.

Organicell Regenerative Medicine, Inc. (OCEL)

Stock analysis · OTC · Healthcare · Biotechnology

$2.74

Market Cap

$19.97M

PE (TTM)

-4.73

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.36

Day Range

$2.52 – $2.76

52-wk Range

$0.90 – $4.80

Avg Volume

N/A

Volume

4.74K

Organicell Regenerative Medicine, Inc. (OCEL) is a publicly traded company in the Healthcare sector. Latest price: $2.74. Market cap $19.97M. Trailing PE -4.73. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Proprietary Signals

Signal snapshot temporarily unavailable.

About Organicell Regenerative Medicine, Inc.

Organicell Regenerative Medicine, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering biological therapies for degenerative conditions. Their primary investigational product is Zofin, an acellular biological treatment sourced from perinatal material. This therapeutic is specifically processed to preserve its inherent microRNAs, without the inclusion of any artificial additives or diluents. Zofin is currently undergoing Phase I/II clinical evaluation for its efficacy against COVID-19. Beyond its core drug development, Organicell also offers independent educational, promotional, and marketing solutions to various healthcare sectors, including medical, anti-aging, and regenerative service providers. The company maintains key research collaborations: one with the Centers for Disease Control and Prevention (CDC) to explore Zofin's anti-inflammatory and anti-infective capabilities in experimental influenza models, and another with Oklahoma State University to assess Zofin's potential in treating severe respiratory illnesses stemming from viruses with pandemic risk. Founded in 2011, this Miami, Florida-based company initially operated as Biotech Products Services and…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-4.73×
P/S (TTM)	2.86×
P/B	29.88×
PEG	0.16×
P/FCF (TTM)	-14.80×
EV / EBITDA	236.69×
EV / Sales	2.61×
Earnings Yield	-18.26%
Free Cash Flow Yield	-6.76%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$18.22M
Revenue (TTM)	$6.99M
Net Income (TTM)	-$3.65M
Free Cash Flow (TTM)	-$1.51M
Net Debt	-$1.75M
Working Capital	$155.00K
Gross Margin	81.52%
Operating Margin	-59.10%
Net Margin	-55.59%
Return on Equity	455.87%
Return on Invested Capital	-511.01%